Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity

被引：0
|
作者：
Breitbart, Eyal [1 ]
Mendel, Itzhak [1 ]
Yacov, Niva [1 ]
机构：
[1] VBL Therapeut, Or Yehuda, Israel
来源：
MOLECULAR THERAPY | 2017年 / 25卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
585
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [41] ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Youqian Wu
    Chao Zhang
    Xiaolan Liu
    Zhengfu He
    Bing Shan
    Qingxin Zeng
    Qingwei Zhao
    Huaying Zhu
    Hongwei Liao
    Xufeng Cen
    Xiaoyan Xu
    Mengmeng Zhang
    Tingjun Hou
    Zhe Wang
    Huanhuan Yan
    Shuying Yang
    Yaqin Sun
    Yanying Chen
    Ronghai Wu
    Tingxue Xie
    Wei Chen
    Ayaz Najafov
    Songmin Ying
    Hongguang Xia
    Nature Communications, 12
  • [42] Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
    Shi, Chengyu
    Wang, Ying
    Wu, Minjie
    Chen, Yu
    Liu, Fangzhou
    Shen, Zheyuan
    Wang, Yiran
    Xie, Shaofang
    Shen, Yingying
    Sang, Lingjie
    Zhang, Zhen
    Gao, Zerui
    Yang, Luojia
    Qu, Lei
    Yang, Zuozhen
    He, Xinyu
    Guo, Yu
    Pan, Chenghao
    Che, Jinxin
    Ju, Huaiqiang
    Liu, Jian
    Cai, Zhijian
    Yan, Qingfeng
    Yu, Luyang
    Wang, Liangjing
    Dong, Xiaowu
    Xu, Pinglong
    Shao, Jianzhong
    Liu, Yang
    Li, Xu
    Wang, Wenqi
    Zhou, Ruhong
    Zhou, Tianhua
    Lin, Aifu
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [43] ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Wu, Youqian
    Zhang, Chao
    Liu, Xiaolan
    He, Zhengfu
    Shan, Bing
    Zeng, Qingxin
    Zhao, Qingwei
    Zhu, Huaying
    Liao, Hongwei
    Cen, Xufeng
    Xu, Xiaoyan
    Zhang, Mengmeng
    Hou, Tingjun
    Wang, Zhe
    Yan, Huanhuan
    Yang, Shuying
    Sun, Yaqin
    Chen, Yanying
    Wu, Ronghai
    Xie, Tingxue
    Chen, Wei
    Najafov, Ayaz
    Ying, Songmin
    Xia, Hongguang
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [44] Anti-Tumor Responses By Ibrutinib and Anti-PD-1 Blockade Is Enhanced By Phosphatidylserine-Targeting Antibody Therapy
    Gong, Jian
    Gray, Michael
    Hutchins, Jeff
    Freimark, Bruce
    BLOOD, 2016, 128 (22)
  • [45] Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
    Jinrui Zhang
    Ge Zhang
    Wenjing Zhang
    Lu Bai
    Luning Wang
    Tiantian Li
    Li Yan
    Yang Xu
    Dan Chen
    Wenting Gao
    Chuanzhou Gao
    Chaoqun Chen
    Menglin Ren
    Yuexia Jiao
    Hongqiang Qin
    Yu Sun
    Lili Zhi
    Yangfan Qi
    Jinyao Zhao
    Quentin Liu
    Han Liu
    Yang Wang
    Cell Death & Differentiation, 2022, 29 : 2247 - 2261
  • [46] Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
    Zhang, Jinrui
    Zhang, Ge
    Zhang, Wenjing
    Bai, Lu
    Wang, Luning
    Li, Tiantian
    Yan, Li
    Xu, Yang
    Chen, Dan
    Gao, Wenting
    Gao, Chuanzhou
    Chen, Chaoqun
    Ren, Menglin
    Jiao, Yuexia
    Qin, Hongqiang
    Sun, Yu
    Zhi, Lili
    Qi, Yangfan
    Zhao, Jinyao
    Liu, Quentin
    Liu, Han
    Wang, Yang
    CELL DEATH AND DIFFERENTIATION, 2022, 29 (11): : 2247 - 2261
  • [47] Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
    Zha, Haoran
    Han, Xiao
    Zhu, Ying
    Yang, Fei
    Li, Yongsheng
    Li, Qijing
    Guo, Bo
    Zhu, Bo
    ONCOIMMUNOLOGY, 2017, 6 (10):
  • [48] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [49] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Topalian, Suzanne L.
    Drake, Charles G.
    Pardoll, Drew M.
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
  • [50] Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment
    Li, Jie
    Cao, Peiyu
    Chen, Yuxin
    Wang, Junqi
    Sun, Xiaolei
    Chen, Renfu
    Wang, Gang
    Hou, Jianquan
    EXPERIMENTAL CELL RESEARCH, 2022, 417 (01)
12345